Baxter (BAX) Q4 2025 earnings review
Sales Grow, But Profits & Guidance Disappoint
New CEO Andrew Hider's cleanup continues, but the financial pain is intensifying. While Q4 revenue grew 8% (3% operational), earnings quality deteriorated significantly. Adjusted EPS fell 24% YoY to $0.44, missing the company's own prior expectations due to unfavorable mix and tax rates. A massive $485 million goodwill impairment in Front Line Care and a $330 million tax valuation allowance resulted in a GAAP loss of over $1 billion. Looking ahead, the turnaround will be slow: FY26 guidance projects flat sales and an earnings contraction to $1.85–$2.05 per share.
🐂 Bull Case
The Advanced Surgery portfolio remains a reliable growth engine, contributing to Medical Products & Therapies' 4% operational growth despite infusion headwinds. Demand remains robust globally.
CEO Andrew Hider is aggressively simplifying the organization. The dividend cut to $0.01 optimizes capital for deleveraging, and the new decentralized model aims to improve the company's historically poor 'say-do ratio'.
🐻 Bear Case
The shipment and installation hold on the Novum IQ Large Volume Pump continues to drag down the Infusion segment. There is no clear timeline for resolution, and customers may eventually switch to competitors.
FY26 Adjusted EPS guidance of $1.85–$2.05 represents a significant decline from the $2.27 delivered in FY25. This signals that margin compression and operational headwinds will persist for another year.
⚖️ Verdict: 🔴
Bearish. Revenue stability is the only silver lining in a quarter defined by a massive GAAP loss, a 24% drop in adjusted earnings, and guidance that forecasts shrinking profits in FY26. The turnaround is in early stages and high execution risk remains.
Key Themes
Front Line Care Impairment
Management recorded a $485 million goodwill impairment charge related to the Front Line Care reporting unit (part of Hillrom acquisition). This admits that the asset is underperforming original expectations and raises concerns about the long-term value of the Connected Care portfolio.
Infusion Systems Drag
The Medical Products & Therapies segment is fighting with one hand tied behind its back. While IV solutions grew due to easy comps, infusion systems sales fell due to the Novum IQ Large Volume Pump hold. This hold is not just a revenue issue; it opens the door for competitors to take share in sticky hospital contracts.
Drug Compounding Momentum
Drug Compounding continues to outperform, growing 18% operationally in Q4. This segment is capitalizing on strong demand and helping offset weakness in the Injectables & Anesthesia business.
Tax Asset Write-Down
Baxter recorded a $330 million valuation allowance against U.S. deferred tax assets. In plain English: the company does not expect to generate enough taxable income in the near future to utilize these assets. This is a vote of no-confidence in near-term U.S. profitability.
Capital Allocation Reset
The dividend has been effectively eliminated (cut to $0.01/share). While painful for income investors, this was necessary to redirect cash toward debt repayment. Management reiterated the focus on 'strengthening the balance sheet' as a precursor to any future growth investments.
Other KPIs
A massive loss driven by non-cash charges: $485M goodwill impairment and $330M tax valuation allowance. Even excluding these, adjusted earnings fell. This highlights the gap between 'operational' metrics and the actual accounting reality.
Decelerating. Segment operating margin fell from 16.5% a year ago to 15.4%, despite sales growing. This indicates negative operating leverage, likely due to the manufacturing overhead associated with the stalled Novum pump production.
Improvement from $373M in FY24, but still low relative to the company's size and debt load. The dividend cut will save ~$300M annually, which is critical given this level of cash generation.
Guidance
Decelerating. FY25 reported sales grew 6%. The guidance for 2026 implies stagnation, reflecting the persistent drag from the Novum hold and potential divestiture impacts/exits (like China IV solutions).
Decelerating. This is a sharp drop from the $2.27 delivered in FY25 (Continuing Ops). Management cites 'unfavorable product mix' and tax rates, but a ~14% earnings decline during a turnaround is a major red flag.
Decelerating vs FY25's +3%. This confirms that the core business is not growing volume, likely due to the combined effects of the pump hold and sluggish hospital utilization.
Key Questions
Novum IQ Timeline
The Novum IQ hold is now a multi-quarter drag. When specifically does management expect to resume shipments, and how much market share has permanently shifted to competitors during this pause?
Front Line Care Impairment
A $485M impairment in Front Line Care suggests the Hillrom integration is failing to meet targets. Is this purely accounting, or has the long-term growth profile of the connected care business structurally deteriorated?
Tax Valuation Allowance
The $330M tax valuation allowance implies you don't expect to generate sufficient taxable income in the U.S. soon. How does this reconcile with the narrative of a turnaround and stabilization in 2026?